It is “abemaciclib”, a potent cyclin inhibitor, which would be added to the usual treatments of surgery, radiotherapy and hormone therapy for two years.
That’s how he made it known Valeria Cáceres, Head of the Clinical Oncology Department of the Ángel H. Roffo Institute of Oncology, in conversation with the Télam Agency. “Abemaciclib, which is a cyclin inhibitor, is added for two years to the usual treatments of surgery, radiotherapy and hormone therapy. What we have seen is that, in a subset of high-risk patients, the risk of relapse”He explained.
The specialist explained that what this new drug does is “stop the cell cycle” and, in this way, puts the cell in a state of immobility so that it does not continue to replicate.
“There are specifically drugs that are called” cyclin inhibitors “, which are proteins that are involved in cell duplication and there are three types – abemaciclib, palbociclib and ribociclib -, but the only one that has shown benefits in early disease, that is, in the disease that has not yet spread to other organs, it is abemaciclib “He added.
“Abemaciclib is a new drug which, when added to hormone therapy, during the first two years of therapy, reduces the number of relapses when compared with hormone therapy alone. It is used in patients with HER2-positive and HER2-negative breast cancer who , on the other hand, it is the most common type of breast cancer, and also at high risk “he also explained to Télam Victoria Costanzo, oncologist at the Alexander Fleming Institute’s Breast Clinical Oncology Service.
The difference with abemaciclib, according to the specialist, is that it is part of the group of so-called “targeted therapies”, which are the most modern therapies in oncology, where a molecular alteration responsible for the growth of a type of cancer is found and cancer therapy it is aimed at this affectation.
Furthermore, he said: “Most cases of breast cancer are sporadic, meaning they are not related to history or heredity and we cannot prevent it from happening. What we can prevent is the onset of an invasive disease or detect it at an early stage where be treatable, and with as little medical aggression as possible “.
What good news!
–
